靶向假基因RPSAP52可抑制卵巢癌患者来源原位异种移植模型的肿瘤生长
研究探讨假基因RPSAP52在卵巢癌中的作用及反义寡核苷酸靶向治疗的临床前可行性。RPSAP52在卵巢癌患者样本和临床前模型中与HMGA2共过表达,其高表达与早期患者预后不良相关并可对I–II期患者分层。特异性沉默RPSAP52在体外和体内均抑制肿瘤生长,LNA GapmeR在细胞系和PDOX模型中显示显著抗肿瘤效果且无明显毒性。
要点
- RPSAP52在卵巢癌中过表达并与HMGA2共表达,高表达提示早期患者预后不良。
- 沉默RPSAP52可抑制卵巢癌体外和体内肿瘤生长。
- 靶向RPSAP52的LNA GapmeR在PDOX模型中显示抗肿瘤效果且无明显毒性。
核心结论
- RPSAP52在卵巢癌中具有促生长特征,可作为潜在治疗靶点及早期预后生物标志物。
研究设计与样本
- 利用TCGA卵巢癌数据、原位PDX模型和商业细胞系分析RPSAP52与HMGA2表达。
- 采用Kaplan-Meier法在TCGA卵巢癌队列数据集中评估RPSAP52表达相关生存。
- 通过慢病毒介导耗竭和针对RPSAP52的反义LNA GapmeR评估体外和体内肿瘤生长效应。
主要发现
- RPSAP52在卵巢癌患者样本和临床前模型中过表达,并与HMGA2过表达一致。
- RPSAP52在卵巢癌早期阶段高表达与较差临床结局相关,并可对I期和II期患者进行分层。
- 特异性耗竭RPSAP52导致卵巢癌体外和体内肿瘤生长减少。
- 针对RPSAP52的反义LNA GapmeR在卵巢癌细胞系和PDOX模型中显示显著抗肿瘤效果且无明显毒性。
临床怎么用
- RPSAP52高表达或可作为卵巢癌早期预后分层指标。
- 反义LNA GapmeR靶向RPSAP52是卵巢癌潜在治疗策略,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The RPSAP52 pseudogene is transcribed in the opposite direction to the oncofetal gene HMGA2 and is reexpressed in various human cancers. Here, we investigate the impact of RPSAP52 in ovarian cancer (OC) and explore the potential therapeutic application of GapmeR antisense oligonucleotides against RPSAP52 in preclinical models. RPSAP52 and HMGA2 expression were investigated in TCGA for OC and further explored in a panel of orthotopic PDXs and commercial cell lines by RT-qPCR. The Kaplan-Meier method was used to estimate survival associated with RPSAP52 expression in a dataset within the OC TCGA cohort. The effect of specific silencing of RPSAP52 on tumor growth in vitro and in vivo was evaluated by lentiviral-mediated depletion and antisense LNA GapmeRs against RPSAP52. The pseudogene RPSAP52 was overexpressed in epithelial OC in both patient samples and OC preclinical models coinciding with the overexpression of HMGA2. Elevated expression levels of RPSAP52 in the early stages of OC were associated with poorer clinical outcomes and could stratify patients in stages I and II. The specific depletion of RPSAP52 led to a reduction in OC tumor growth in vitro and in vivo. Furthermore, the treatment with antisense LNA GapmeRs against RPSAP52 showed significant antitumoral effect in OC cell lines and in a PDOX model (without evident toxicity). Our findings demonstrate that RPSAP52 displays pro-growth features in OC, underscoring the significance of pseudogenes in cancer pathophysiology. This pseudogene has potential utility as therapeutic target in OC and as valuable prognostic biomarker for the early stages of this disease.
引用
- Ramesh-Kumar D, Sánchez-Castillo A, Soler M, et al. Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models. Eur J Cancer. 2025. PMID: 41075454. doi:10.1016/j.ejca.2025.116040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。